Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606615 | 0.93 | TSHR (0.41) | TSHRPPARACA1CA2CA12 | |
| SCHEMBL4539773 | 0.85 | — | — | |
| SCHEMBL15561977 | 0.79 | PPARA (0.40) | TSHRPPARACA1CA2CA12 | |
| SCHEMBL17853470 | 0.77 | PPARA (0.43) | TSHRPPARACA1CA2CA12 | |
| SCHEMBL1486780 | 0.74 | — | — | |
| SCHEMBL7357296 | 0.73 | — | — | |
| SCHEMBL5897405 | 0.73 | PPARA (0.43) | TSHRPPARACA1CA2TP53 | |
| SCHEMBL195895 | 0.73 | TSHR (0.43) | TSHRPPARACA1CA2CA12 | |
| SCHEMBL1678870 | 0.67 | — | — | |
| SCHEMBL386176 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846808-A2 | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-07-14 | — | — | EP | claimed |
| US-9949966-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMAN-LA ROCHE INC. (US) | 2018-04-24 | — | — | US | claimed |
| EP-3099685-B1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | claimed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | claimed |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-10-13 | — | — | US | claimed |
| US-9458153-B2 | Dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | claimed |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2016-07-21 | — | — | US | claimed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | claimed |
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HOFFMANN-LA ROCHE INC. (US) | 2015-07-30 | — | — | US | claimed |
| US-7115657-B2 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2006-10-03 | — | — | US | claimed |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | claimed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | claimed |
| EP-4219767-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| CN-109328237-B | Inhibitors of PAPD5 and PAPD7 for the treatment of hepatitis b infection | 豪夫迈·罗氏有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HOFFMANN-LA ROCHE INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | UNI-PHARMA KLEON TSETIS PHARMACEUTICAL LABORATORIES S.A. (GR) | 2004-12-23 | — | — | US | disclosed |
| EP-1301504-B1 | BIFUNCTIONAL AGENTS POSSESSING ANTIOXIDANT AND ANTIARRHYTHMIC ACTIVITY | UNI PHARMA KLEON TSETIS PHARMACEUTICAL LAB SA (GR) | 2004-11-03 | — | — | EP | disclosed |
| EP-1230210-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001036375-A1 | AMINOALCOHOL DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210682-A1 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | TSHR 2541/4885PPARA 2472/4885CA1 4852/4885 |
| US-20040259763-A1 | Bifunctional agents possessing antioxidant and antiarrhythmic activity | GPX4, GSR, GPX1 | TSHR 2133/4885PPARA 1155/4885CA1 1805/4885 |
| US-11191775-B2 | PAPD5 and PAPD7 inhibitors for treating a hepatitis B infection | HAVCR2, BRD7, ZC3HAV1 | TSHR 3962/4885PPARA 3110/4885CA1 3691/4885 |
| US-20160207914-A9 | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis B virus infection | HAVCR2, HCCS, DHX15 | TSHR 2541/4885PPARA 2472/4885CA1 4852/4885 |
| US-20220096527-A1 | PAPD5 AND PAPD7 INHIBITORS FOR TREATING A HEPATITIS B INFECTION | HAVCR2, BRD7, BAZ2B | TSHR 4039/4885PPARA 3238/4885CA1 3973/4885 |
| US-20160296515-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, HCCS, DHX15 | TSHR 2541/4885PPARA 2472/4885CA1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.